@prefix jvr: <http://data.loterre.fr/ark:/67375/JVR> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .

jvr:-L6C0XPHT-4
  skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-G7KXQWSR-5
  skos:prefLabel "biosynthèse (Qualificatif)"@fr, "biosynthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-Z9TSGBXH-4
  skos:prefLabel "génétique (Qualificatif)"@fr, "genetics (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-BFG2KWD6-H
  skos:prefLabel "Récepteur fibronectine"@fr, "Receptors, Fibronectin"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-WZM8N88M-N .

jvr:-Q3979798-W
  skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-H7K65Q8S-Z
  skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TJHVZCRZ-0
  skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-FWD2BGQ0-9
  skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-R0ZCQ8X6-J
  skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-S0CS1X5R-5
  skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-M63HSDM7-1
  skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-T2TS0S41-N
  skos:prefLabel "ultrastructure (Qualifier)"@en, "ultrastructure (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-HQRFT0C6-B
  skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-W6SQV79N-S
  skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr: a skos:ConceptScheme .
jvr:-SBNWSM1T-R
  skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CJXMKG5Q-F
  skos:prefLabel "deficiency (Qualifier)"@en, "déficit (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-D0F21513-5
  skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NHL3D2X0-S
  skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-QWH5TZ0R-S
  skos:prefLabel "Receptors, Lymphocyte Homing"@en, "Récepteurs d'écotaxie des lymphocytes"@fr ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-WZM8N88M-N .

jvr:-N2WP45CN-V
  skos:prefLabel "drug effects (Qualifier)"@en, "effets des médicaments et des substances chimiques (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-WZM8N88M-N
  skos:altLabel "alpha4beta1 Integrin"@en, "VLA-4"@en, "Antigène-4 très tardif"@fr, "Antigène-4 d'activation très tardive"@fr, "Very Late Activation Antigen-4"@en, "Very Late Antigen-4"@en, "Integrin alpha(4)beta(1)"@en, "VLA-4 (Very Late Antigen-4)"@fr, "Integrin Heterodimer alpha4beta1"@en, "CD49d-CD29"@en, "CD49d-CD29"@fr ;
  skos:prefLabel "Integrin alpha4beta1"@en, "Intégrine alpha4bêta1"@fr ;
  mesh:allowableQualifier jvr:-G7KXQWSR-5, jvr:-WZF2ZR3L-B, jvr:-W6SQV79N-S, jvr:-Q3979798-W, jvr:-Z9TSGBXH-4, jvr:-S0CS1X5R-5, jvr:-SBNWSM1T-R, jvr:-M63HSDM7-1, jvr:-T2TS0S41-N, jvr:-CJXMKG5Q-F, jvr:-H7K65Q8S-Z, jvr:-R0ZCQ8X6-J, jvr:-NHL3D2X0-S, jvr:-L6C0XPHT-4, jvr:-FWD2BGQ0-9, jvr:-N2WP45CN-V, jvr:-D0F21513-5, jvr:-TJHVZCRZ-0, jvr:-HQRFT0C6-B ;
  skos:broader jvr:-K8VZ7GBS-8, jvr:-BFG2KWD6-H, jvr:-QWH5TZ0R-S ;
  skos:definition "Integrin alpha4beta1 is a FIBRONECTIN and VCAM-1 receptor present on LYMPHOCYTES; MONOCYTES; EOSINOPHILS; NK CELLS and thymocytes. It is involved in both cell-cell and cell- EXTRACELLULAR MATRIX adhesion and plays a role in INFLAMMATION, hematopoietic cell homing and immune function, and has been implicated in skeletal MYOGENESIS; NEURAL CREST migration and proliferation, lymphocyte maturation and morphogenesis of the PLACENTA and HEART."@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:inScheme jvr: ;
  dc:created "2002-07-02"^^xsd:date ;
  dc:modified "2017-05-24"^^xsd:date ;
  dc:established "2003-01-01"^^xsd:date ;
  owl:sameAs <http://id.nlm.nih.gov/mesh/D039041> .

jvr:-K8VZ7GBS-8
  skos:prefLabel "Récepteur VLA"@fr, "Receptors, Very Late Antigen"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-WZM8N88M-N .

jvr:-WZF2ZR3L-B
  skos:prefLabel "physiology (Qualifier)"@en, "physiologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .